Sylvester Comprehensive Cancer Center

  • DCC-2618-01-001 - De La Fuente, Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:
    RCemailImg Mirna Gonzalez
    RCphone 3052432441

    IRB: 20170452

    		SDG: Neurological Cancer
    Disease Site(s):

    Esophagus,Brain and Nervous System,Other Hematopoietic,Stomach,Small Intestine,Colon,Rectum,Other Digestive Organ
    Sponsor: DECIPHERA

    Enrolling Sites:

    Sylvester
    Title:

    DCC-2618-01-001: A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety,Tolerability, Efficacy, and Pharmacokinetics in Patients with AdvancedMalignancies
    Eligibility Criteria - NCT02571036 *This information has been extracted from " www.clinicaltrials.gov"

  • PT2977-101 - De La Fuente, Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:
    RCemailImg Isabel Fernandez
    RCphone 3052435486

    IRB: 20170815

    		SDG: Neurological Cancer
    Disease Site(s):

    Kidney,Brain and Nervous System
    Sponsor: Peloton

    Enrolling Sites:

    Sylvester
    Title:

    PT2977-101: A Phase 1, Dose-Escalation and Expansion Trial of PT2977, a HIF-2a Inhibitor, in Patients With Advanced Solid Tumors
    Eligibility Criteria - NCT02974738 *This information has been extracted from " www.clinicaltrials.gov"

  • 20180606 - De La Fuente Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:
    RCemailImg Nathalie Padron
    RCphone 3052433530

    IRB: 20180606

    		SDG: Neurological Cancer
    Disease Site(s):

    Brain and Nervous System
    Sponsor: SCCC

    Enrolling Sites:

    Sylvester
    Title:

    Non-invasive glioma characterization through molecular imaging
    Eligibility Criteria - NCT03684109 *This information has been extracted from " www.clinicaltrials.gov"

  • 2102-ONC-102 - De La Fuente, Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:
    RCemailImg Nailet Real Bestard
    RCphone 3052438173

    IRB: 20180721

    		SDG: Neurological Cancer
    Disease Site(s):

    Brain and Nervous System,Pancreas,Bones and Joints,Soft Tissue
    Sponsor: FORMA

    Enrolling Sites:

    Sylvester
    Title:

    2102-ONC-102: A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation
    Eligibility Criteria - NCT03684811 *This information has been extracted from " www.clinicaltrials.gov"

  • A071601 - De La Fuente, Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:
    RCemailImg Alain Fernandez Marrero
    RCphone 3052439553

    IRB: 20180772

    		SDG: Neurological Cancer
    Disease Site(s):

    Brain and Nervous System
    Sponsor: Alliance for Clinical Trials in Oncology

    Enrolling Sites:

    Sylvester
    Title:

    A071601: Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
    Eligibility Criteria - NCT03224767 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191011 - De La Fuente Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:
    RCemailImg Nathalie Padron
    RCphone 3052433530

    IRB: 20191011

    		SDG: Neurological Cancer
    Disease Site(s):

    Brain and Nervous System
    Sponsor: Agios

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
    Eligibility Criteria - NCT04164901 *This information has been extracted from " www.clinicaltrials.gov"

  • GSK3326595 - Lossos, Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    		Coordinator:
    RCemailImg Lilia Curbelo
    RCphone 3052435803

    IRB: 20180040

    		SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Breast,Brain and Nervous System,Non-Hodgkin Lymphoma
    Sponsor: GLAXOSMITHKLINE GROUP

    Enrolling Sites:

    Sylvester
    Title:

    GSK204653: A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma
    Eligibility Criteria - NCT02783300 *This information has been extracted from " www.clinicaltrials.gov"

  • NRG-BN003 - Mellon, Eric

  • Investigator:
    Eric Mellon
    RCname Email

    		Coordinator:
    RCemailImg Raymond Vado
    RCphone 3052436809

    IRB: 20170631

    		SDG: Neurological Cancer
    Disease Site(s):

    Brain and Nervous System
    Sponsor: NRG

    Enrolling Sites:

    Deerfield
    JMH
    Sylvester
    Title:

    NRG-BN003:Phase III Trial Of Observation Versus Irradiation For A Gross Totally Resected Grade II Meningioma
    Eligibility Criteria - NCT03180268 *This information has been extracted from " www.clinicaltrials.gov"

  • CCTG CE.7 - Mellon, Eric

  • Investigator:
    Eric Mellon
    RCname Email

    		Coordinator:
    RCemailImg Lilly Sanchez
    RCphone 3052430974

    IRB: 20190176

    		SDG: Neurological Cancer
    Disease Site(s):

    Brain and Nervous System
    Sponsor: NRG

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    Title:

    CCTG CE.7: A Phase III Trial of Stereotactic Radiosurgery Compared With Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases
    Eligibility Criteria - NCT03550391 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191167 - Mellon Eric

  • Investigator:
    Eric Mellon
    RCname Email

    		Coordinator:

    IRB: 20191167

    		SDG: Neurological Cancer
    Disease Site(s):

    Brain and Nervous System
    Sponsor: Alliance for Clinical Trials in Oncology

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    UMH
    Title:

    Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared With Fractionated SRS for Resected Metastatic Brain Disease
    Eligibility Criteria - NCT04114981 *This information has been extracted from " www.clinicaltrials.gov"

  • C-500-01 - Perez, Cesar

  • Investigator:
    Cesar Perez
    RCname Email

    		Coordinator:
    RCemailImg Chinar Singh
    RCphone 3052438237

    IRB: 20160238

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Brain and Nervous System,Leukemia, Other,Bones and Joints,Melanoma, skin
    Sponsor: Agenus

    Enrolling Sites:

    Sylvester
    Title:

    C-500-01
    Eligibility Criteria - NCT02694822 *This information has been extracted from " www.clinicaltrials.gov"